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OBJECTIVES We sought to develop a prognostic model to predict the disappearance of left atrial thrombi
(LAT) among candidates for percutaneous transvenous mitral commissurotomy (PTMC).
BACKGROUND Complete LAT resolution can be achieved with oral anticoagulation, allowing a number of
patients to safely undergo PTMC.
METHODS We randomly allocated 108 PTMC candidates with LAT into two subsets—one to derive
the model and the other to validate it. The existence of LAT and its size were measured by
transesophageal echocardiography. Patients were given oral anticoagulation and followed up
for 6 to 34 months. There was a 62% disappearance rate of LAT.
RESULTS We developed the following model: P  1/(1  exponential [8.1  1.8 NYHA  0.7
area]), where NYHA  New York Heart Association functional class (from I to IV), and
area  LAT area (in cm2). The model was well calibrated (goodness-of-fit test, p  0.82) and
well discriminated (area under the receiver-operating characteristics [ROC] curve  0.92).
Performance in the validating sample was equally good (area under the ROC curve  0.94;
goodness-of-fit test, p  0.16). When a cut-off point of p  0.7 was used to designate the
LAT disappearance in the validating set, the model had a sensitivity, specificity and positive
and negative predictive values of 93.3%, 79.2%, 84.9% and 90.5%, respectively.
CONCLUSIONS Combined clinical (NYHA functional class) and echocardiographic (LAT area) variables are
predictive of the 34-month outcome of oral anticoagulation for LAT resolution among
PTMC candidates. This simple and highly predictive model might be potentially useful for
clinical assessment and proper management. (J Am Coll Cardiol 2002;39:886–91) © 2002
by the American College of Cardiology Foundation
Percutaneous transvenous mitral commissurotomy (PTMC)
has been used successfully as an alternative to surgical
treatment in patients with symptomatic, severe mitral ste-
nosis, particularly when regurgitation and valvular calcifica-
tions are limited (1–10). The presence of a left atrial
thrombus (LAT) is generally considered a contraindication
to this procedure, because of embolic risk, which may arise
when catheters and wires are manipulated in the left atrium
(1–3,8). Recent reports have demonstrated that, in some
circumstances, complete resolution of LAT can be achieved
with oral anticoagulant therapy, allowing patients to un-
dergo PTMC safely (11–15). However, to date, no study
has attempted to develop a prognostic model to predict such
success. A model would be particularly useful in developing
countries, where surgical treatment is relatively expensive
and unable to meet the demand. Knowing the likelihood of
LAT disappearance would help the physician decide
whether to proceed with surgical repair or to continue oral
anticoagulation until LAT resolution and then to perform
PTMC.
The purpose of our study was to develop and validate a
simple model to predict the likelihood of LAT disappear-
ance among PTMC candidates receiving long-term oral
anticoagulant therapy.
METHODS
Study group. Our prospective cohort study was conducted
at Khon Kaen University Hospital between August 1996
and October 2000. All patients with mitral stenosis who
were candidates for PTMC were consecutively recruited.
The candidates had symptomatic (16), severe mitral steno-
sis, with a total echocardiographic score of 11 for the
mitral valve and a mitral regurgitation score of 2 (17).
Both transthoracic echocardiography (TTE) and multiplane
transesophageal echocardiography (TEE) were performed
in all patients before PTMC. Patients receiving an oral
anticoagulant more than 72 h previously or who had a
contraindication to TEE were excluded.
Echocardiographic method and variables. Standard TTE
and multiplane TEE studies (18) were performed using a
color Doppler system (2.5 or 3.5 MHz) and multiplane
transducer (5.0-MHz; Hewlett-Packard Imaging System
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Sonos 1000 and since August 1999, 5000), respectively.
Transesophageal echocardiography was performed within
24 h of the TTE study by echocardiographers who were
unaware of the TTE findings. Left atrial thrombus was
diagnosed according to the presence of an intracavitary
echogenic mass clearly distinct from the left atrial endocar-
dium and the pectinate muscles, and it was visualized on at
least two different planes (18). The maximal area of LAT
was measured by planimetry utilizing the built-in echocar-
diographic system’s software. Left atrial spontaneous echo
contrast (LASEC) was characterized by dynamic clouds of
echoes within the left atrial cavity. The severity of LASEC
was graded from 0 to 4, as described by Fatkin et al. (19).
The observation of LASEC was standardized by varying
both the gain and compress settings throughout their full
range during each study. We measured left atrial diameter at
the end of systole (from the parasternal view), mitral valve
area (by both planimetry from two-dimensional echocardi-
ography and the continuous wave Doppler pressure half-
time method) and the mitral valve echocardiographic score
(17).
Both TTE and TEE findings were recorded on VHS
videotape for subsequent review to identify LAT and
LASEC and to determine the maximal area and mobility of
the LAT. All echocardiographic measurements were done
independently by three echocardiographers. Any differences
among them regarding the recognition of either LAT or
LASEC were resolved by consensus. Written, informed
consent was obtained from each patient, and the research
protocol was approved by our institutional Ethics Commit-
tee.
Left atrial thrombi were detected by TEE in all 108
patients (in the left atrial appendage of all patients and in
the left atrial body of 15 patients) and by TTE in only 18
patients. Transesophageal echocardiography revealed
LASEC in all 108 patients, whereas TTE could detect
LASEC in only 16.
Management of the patients. After identification of LAT,
all patients were given oral anticoagulant therapy, maintain-
ing the therapeutic range of the international normalized
ratio (INR) of 2.0 to 3.0 (20). The outcome of LAT was
serially studied using both TTE and TEE after the first six
months and subsequently, depending on the clinical indi-
cations, until complete resolution of LAT or just before
mitral valve surgery. Percutaneous transvenous mitral com-
missurotomy was performed as soon as possible after com-
plete resolution of LAT.
Statistical analysis. We randomly allocated the 108 sub-
jects into two subsets of 54 each—the training set and the
validating set. Identification of candidate variables was
based only on the 37 outcomes of the training set. Inde-
pendent variables for the model were identified prospec-
tively to avoid increased risk of type I errors. Initially,
predictors of LAT resolution were identified by the inves-
tigators; then the effect of each potential predictor was
examined using univariate logistic regression. To avoid
over-fitting the predictive model, we limited the number of
candidate variables in the initial model to four, based on the
size of the study group and the number of outcomes (21), as
well as on the strength of the relationship to LAT disap-
pearance obtained in the univariate analysis, data availability
before oral anticoagulant therapy and fewer measurement
errors in practice.
We applied methods for development of prognostic
models used by Kleinbaum et al. (22) and Hosmer and
Lemeshow (23). Continuous variables were tested for the
linear relationship assumption, using a restricted cubic
spline allowing three knots (24). Because there was no
departure from linearity, the variables were entered in their
original form. Model fitting was done using backward
elimination; the variables were removed, one at a time, if the
p value of the likelihood ratio test was 0.05. The adequacy
of the model and testing of goodness-of-fit were examined
according to Hosmer and Lemeshow (23). Once the final
model was obtained, the receiver-operating characteristics
(ROC) curve (25) was constructed. The area under the
ROC curve and its 95% confidence interval (CI) were then
estimated.
The model was presented as a logistic function: P  1/(1
 Exp [(  X)]), where  refers to the constant and 
is the coefficient to be estimated. P was the probability of
LAT resolution, which can also be viewed as the risk score,
and X was the predictor. Exp was the exponential function
(raising the natural log to the [(  X)] power) (23).
From the ROC curve, the optimal cut-off point was
determined, which is the value of P that maximizes both the
sensitivity and specificity of the model.
The model was validated using the validating set. The
ROC curve was reconstructed, and the area under the ROC
curve and its 95% CI were estimated. Testing for the
equality of the area under the two ROC curves was
performed according to Cleves (26). The diagnostic perfor-
mance of the model for sensitivity, specificity and positive
and negative predictive values was estimated together with
their 95% CIs. All analyses were performed using STATA,
version 6 (StataCorp, College Station, Texas). A nomogram
was constructed based on the model and the range of values
of all variables in the model.
Abbreviations and Acronyms
CI  confidence interval
INR  international normalized ratio
LASEC  left atrial spontaneous echo contrast
LAT  left atrial thrombus
NYHA  New York Heart Association
PTMC  percutaneous transvenous mitral
commissurotomy
ROC  receiver-operating characteristics
TEE  transesophageal echocardiography
TTE  transthoracic echocardiography
887JACC Vol. 39, No. 5, 2002 Silaruks et al.
March 6, 2002:886–91 Prognostic Model of Left Atrial Thrombi Resolution
RESULTS
Total patients and magnitude of the outcome. Among a
total of 494 consecutive patients with symptomatic, severe
mitral stenosis, 379 were candidates for PTMC. Among
these PTMC candidates, 108 with documented LAT com-
prised the study cohort (age range 19 to 60 years; mean
[SD] 40.1  7.6 years). The duration of follow-up ranged
from 6 to 34 months (mean [SD] 12.2  6.2 months;
median 11 months). A total of 1,209 patient-months were
observed. Complete resolution of LAT was demonstrated in
67 patients (62%), with an overall thrombus disappearance
rate of 5.25 per 100 patient-months under observation (95%
CI 3.96 to 6.97) or 63.0 per 100 patients per year (95% CI
47.5 to 83.6). All 67 patients subsequently underwent
PTMC successfully. There were no procedure-related com-
plications during or immediately after PTMC. None of the
patients with LAT in the atrial body (n  15) had LAT
resolution, so all of them underwent mitral valve surgery.
None of our patients was receiving oral anticoagulant
therapy before the study.
There were 26 systemic embolic events (2.1 per 100
patient-months) before study entry, but none of these
patients developed a clinical embolism after starting oral
anticoagulant therapy. During follow-up, the only bleeding
complication was minor (n  11).
Patient characteristics of the training set. Of 54 patients
in this set, the LAT completely resolved in 37 (68.5%). The
follow-up duration ranged from 6 to 28 months (median
10.5 months). The patients’ age ranged from 19 to 60 years
(mean [SD] 40.0  7.7 years). Approximately two-thirds
of the patients were female. The baseline clinical and
echocardiographic characteristics are summarized in Table
1.
Development of the prognostic model. Fourteen poten-
tial predictors of LAT resolution were prospectively speci-
fied. However, the data in our training set allowed for only
11 of them to be examined for their effects in the univariate
logistic regression (Tables 2 and 3). The effects of the
remaining three variables (including LASEC, mitral valve
area and pressure half-time) were not examined, because of
the small sample size.
Among the 11 variables, five were statistically significant
with respect to the outcome (p  0.05). These included: 1)
the presence of atrial fibrillation; 2) New York Heart
Association (NYHA) functional class; 3) mitral valve score;
4) left atrial size; and 5) LAT area. We discarded the mitral
valve score, because its measurement was prone to error in
practice. Thus, four candidate variables remained for the
initial multivariable model (Table 4). However, the effects
Table 1. Baseline Characteristics of Patients in the Training Set
(n  54)
Variables
Age (yrs) 40.0  7.7
Atrial fibrillation 21 (38.9%)
Left atrial end-systolic dimension (mm) 5.2  0.7
Mitral valve area (cm2) 0.8  0.2
Pressure half-time (mm Hg) 323.3  71.7
Left atrial thrombus area (cm2) 2.26  1.0
Total mitral valve echocardiographic score 7.4  1.3
Mean PG across mitral valve (mm Hg) 12.7  3.2
Tricuspid regurgitation PG (mm Hg) 41.5  17.7
LASEC on TEE grade
1 13 (24.1%)
2 22 (40.7%)
3 11 (20.4%)
4 8 (14.8%)
Data are presented as the mean value  SD or number (%) of patients.
LASEC  left atrial spontaneous echo contrast; PG  pressure gradient; TEE 
transesophageal echocardiography.
Table 2. Univariate Logistic Regression: Unadjusted OR of
Each Clinical Variable in Relation to Resolution of LAT
Variables n
LAT
Disappearance
(%) OR 95% CI
p
Value
Age (one-year increase) 54 NA 1.04 0.96–1.12 0.369
Gender 0.623
Male 19 63.2 1.00
Female 35 71.4 1.46 0.45–4.77
Syncope 0.568
Yes 5 80.0 1.94 0.20–18.79
No 49 67.3 1.00
Stroke 0.406
Yes 15 60.0 1.00
No 39 71.8 1.70 0.49–5.90
NYHA functional class
(one-class increase)
54 0.10 0.03–0.37 0.001
Atrial fibrillation 0.038
Yes 21 85.7 4.4 1.1–18.0
No 33 57.6 1.00
CI  confidence interval; LAT  left atrial thrombus; NA  not applicable;
NYHA  New York Heart Association; OR  odds ratio.
Table 3. Univariate Logistic Regression: Unadjusted OR of Each Echocardiographic Variable in
Relation to Resolution of LAT
Variables n
LAT
Disappearance (%) OR 95% CI
p
Value
Aortic regurgitation 0.785
Yes 40 67.5 1.00
No 14 71.4 1.20 0.32–4.57
Mitral valve score (one-score increase) 54 NA 0.20 0.08–0.53 0.001
Mean pressure gradient (one-unit increase) 54 NA 0.95 0.79–1.14 0.593
Left atrial size (1-cm increase) 54 NA 0.28 0.10–0.79 0.017
LAT area (1-cm2 increase) 54 NA 0.44 0.29–0.69 0.001
Abbreviations as in Table 2.
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of atrial fibrillation and left atrial size turned out to be
nonsignificant, and these two variables were removed from
the initial model, without any effect on the model (likeli-
hood ratio test, p  0.961 and 0.941, respectively). Thus,
the final model obtained (Table 5) can be written as:
P  1/1  Exp   8.0827  1.8012 NYHA
 0.7028 area	

Model predictive capability. The area under the ROC
curve of the final model was 0.92 (95% CI 0.85 to 0.99)
(Fig. 1a). The model fits the data well (goodness-of-fit test,
p  0.82). The model was simplified to:
P  1/1  Exp [8.1 1.8 NYHA 0.7 area	)
where P  probability of LAT resolution; NYHA  New
York Heart Association functional class (from I to IV); and
area  area of the LAT (cm2).
Adequacy of the model. Standard residuals and measures
of influence for the logistic regression were calculated to
examine the individual effect of each patient on the model;
none was found to influence it.
Validation of the model. The validating set of 54 patients
was used to validate the model. The baseline characteristics
of the patients were similar to those of the training set. The
LAT completely disappeared in 30 patients (55.6%).
The area under the ROC curve was 0.94 (95% CI 0.90 to
1.00) (Fig. 1b). The performance of the model in the
validating sample was not significantly different from that of
the training set (p  0.462). The model fits the data well
(goodness-of-fit test, p  0.16). The optimal cut-off point
of P, as suggested by the ROC curve, was 0.7.
Assessing the diagnostic performance of the model. The
performance of the model was tested against the validating
set by substituting the true NYHA functional class and
LAT area of each patient into the model to obtain P. We
used a cut-off point of P  0.7 to designate the disappear-
ance of LAT, and then we compared the outcome predicted
by the model (diagnostic test) with the true outcome
(reference standard). The model had a sensitivity of 93.3%
(95% CI 77.9% to 99.2%), specificity of 79.2% (95% CI
57.8% to 99.9%), positive predictive value of 84.9% (95% CI
68.1% to 94.9%) and negative predictive value of 90.5%
(95% CI 69.6% to 98.8%).
Simplification of the model: the nomogram. Based on
our data set, we varied the value of NYHA functional class
from I to IV and LAT area from 0.5 to 12.5 cm2. A
nomogram presenting a line graph for each NYHA func-
tional class was constructed (Fig. 2). A horizontal line
corresponding to P  0.7 indicates the optimal cut-off point
that maximizes the diagnostic performance of the model.
DISCUSSION
Percutaneous transvenous mitral commissurotomy has been
accepted as a safe and effective alternative treatment to
surgery, and it results in a good immediate hemodynamic
outcome, a low complication rate and sustained hemody-
namic and clinical improvement in the majority of symp-
tomatic patients with mitral stenosis (1–10). The presence
of LAT, however, is generally considered a contraindication
to this procedure, leaving the open surgical commissurot-
omy the only treatment option. The reported incidence of
LAT in rheumatic mitral stenosis is between 10% and 25%
(27), as compared with 22% in our study.
Surgical repair of mitral stenosis. In our institution, the
waiting list for mitral valve surgery for patients with severe
mitral stenosis is approximately 9 to 15 months, and during
that time, patients must be given oral anticoagulant therapy
to prevent thromboembolic events. If the probability of
LAT disappearance in a particular patient was known, only
those patients needing surgical repair would be put on the
waiting list, thus allowing those in greatest need to move up
the queue, saving resources and precluding serious compli-
cations. We have tried to achieve this goal by using the data
available in our setting, albeit from a small sample.
Variables of the prognostic model. Atrial fibrillation and
left atrial size were not statistically significant independent
variables. However, the higher the NYHA functional class,
the less likely the LAT was to disappear. The pathophysi-
ology of thrombogenesis in congestive heart failure could be
Table 4. The Initial Multivariable Logistic Regression Model: OR of Each Variable, Adjusted
for Effects of All Other Varibles in Relation to Resolution of LAT
Variables Coefficient Standard Error OR 95% CI p Value
NYHA (one-class increase) 1.8611 0.7641 0.15 0.03–0.69 0.015
LAT area (1-cm2 increase) 0.6467 0.2530 0.52 0.32–0.86 0.011
Atrial fibrillation 0.8981 0.9508 2.45 0.38–15.83 0.345
Left atrial size (1-cm increase) 0.0942 0.7740 0.91 0.20–4.15 0.903
Constant 8.2668 4.4564 — — —
Abbreviations as in Table 2.
Table 5. The Final Model
Variables Coefficient Standard Error OR 95% CI p Value
NYHA (one-class increase) 1.8012 0.7267 0.16 0.04–0.69 0.013
LAT area (1-cm2 increase) 0.7028 0.2384 0.49 0.31–0.79 0.003
Constant 8.0827 2.3242 — — —
Abbreviations as in Table 2.
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explained by Virchow’s original triad of low cardiac output,
aberrant flow through a dilated cardiac chamber or poor
contractility, which all produce “flow abnormalities” that
predispose to intracardiac thrombus formation (28). In
patients with mitral stenosis who have a higher NYHA
functional class, or clinically congestive heart failure, the
severe “stasis” of blood within a dilated left atrial chamber
may reflect not only the higher risk toward thrombus
formation, but also the less likelihood of thrombus resolu-
tion.
During the follow-up period of 34 months (median 12.2),
there were no losses. However, the information on time was
not fully utilized by our logistic regression. Our model
predicted a 34-month outcome of oral anticoagulant ther-
apy for LAT resolution, but the chance of such an outcome
occurring might not be constant over the entire follow-up
period. Cox regression analysis, which might yield a prog-
nostic probability of the outcome at a specified point in
time, was not considered, because we aimed for a simple and
easy-to-understand model. Instead, we used multiple logis-
tic regression analysis and the ROC curve to estimate the
diagnostic performance, including sensitivity, specificity and
predictive values, similar to a conventional two-by-two
table, as used by most clinicians.
Clinical implications of the model. The clinical judgment
of the care provider, regarding the need for surgery, is
usually valid in obvious cases. For example, patients with
NYHA functional class IV or a large LAT size should have
an immediate operation. For a large proportion of the
patients, however, surgical repair was uncertain. The model
could be used to decide which patients should get priority
for surgery and which ones might have LAT resolution, as
well as the chance of each. Clinicians can also use the
nomogram (Fig. 2) as a consultation tool for their patients.
The nomogram can be applied once the NYHA func-
tional class and LAT area of the patient are known. For
example, a patient with an LAT area of 7 cm2 and NYHA
functional class I will have an 80% chance of LAT resolu-
tion. However, patients in class IV will have a very small
chance of LAT resolution, no matter how small the LAT
area; this type of patient needs immediate surgery.
Advantage of the model. This prognostic model includes
only two variables to derive a risk score. It is simple and
highly predictive. To the best of our knowledge, this is the
first predictive model for this type of patient. Our model
was developed using a data set, and it was validated and
confirmed by another data set, ensuring its validity (29,30).
However, our validating cohort was a subset of the study
group using the same health care facilities as the training
one. Further validating studies in different health care
settings are needed to confirm this prognostic tool.
Study limitations. Although this study included the largest
set of PTMC candidates with LAT ever reported, the
sample size is still rather small, specifically concerning the
outcomes of interest. This could have resulted in a lack of
Figure 2. Nomogram for predicting the disappearance of LAT.
Figure 1. Receiver-operating characteristics (ROC) curves for prediction
model derived from (a) the training set (solid line; area under the ROC
curve  0.92) and (b) the validating set (dotted line; area under the ROC
curve  0.94). Test for equivalence of the two area under the ROC curves,
p  0.462.
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association with some potentially important variables in
LAT resolution. We would need a larger sample to dem-
onstrate their association with the disappearance of LAT.
Notwithstanding, our aim was to find a simple predictive
model; one with few variables and a high accuracy of
prediction is preferable, even if some potential risk factors
were consequently excluded. Moreover, we also tried to
limit the number of variables before seeing the results, to
avoid over-fitting the model.
It should also be emphasized that patient compliance
(maintaining the therapeutic dosage of INR) may play an
important role in LAT resolution.
Conclusions. We have derived, checked and externally
validated a prognostic model for predicting LAT resolution
among PTMC candidates receiving long-term oral antico-
agulant therapy. The final model achieves a highly predic-
tive accuracy, requires an easily measurable set of clinical
and TEE findings and can be applied using a simple
nomogram in the medical department of any hospital
equipped with an echocardiograph. Although such a model
cannot replace clinical judgment, it helps both physicians
and patients to make better decisions. To confidently
recommend its use, the establishment of its use in different
health care settings is advised.
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